{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T02:45:39Z","timestamp":1784169939111,"version":"3.55.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100011917","name":"Hormozgan University of Medical Sciences","doi-asserted-by":"publisher","award":["IR.HUMS.REC.1396.133"],"award-info":[{"award-number":["IR.HUMS.REC.1396.133"]}],"id":[{"id":"10.13039\/501100011917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"DOI":"10.1186\/s13063-025-08817-7","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T14:43:08Z","timestamp":1743172988000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparison of ezetimibe and atorvastatin versus atorvastatin alone on short-term major adverse cardiac events after percutaneous coronary intervention, a double-blind placebo-controlled randomized clinical trial"],"prefix":"10.1186","volume":"26","author":[{"given":"Hossein","family":"Farshidi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Badri","family":"Bijani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Alireza","family":"Sobhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farideh","family":"Dastsouz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0211-3829","authenticated-orcid":false,"given":"Shahin","family":"Abbaszadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,28]]},"reference":[{"issue":"12","key":"8817_CR1","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/j.amjcard.2013.08.031","volume":"112","author":"HE Bays","year":"2013","unstructured":"Bays HE, Averna M, Majul C, Muller-Wieland D, De Pellegrin A, Giezek H, et al. Efficacy and safety of ezetimibe added to atorvastatin versus atorvastatin uptitration or switching to rosuvastatin in patients with primary hypercholesterolemia. Am J Cardiol. 2013;112(12):1885\u201395.","journal-title":"Am J Cardiol"},{"issue":"1","key":"8817_CR2","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3109\/14017431.2012.734635","volume":"47","author":"HK Berthold","year":"2013","unstructured":"Berthold HK, Berneis K, Mantzoros CS, Krone W, Gouni-Berthold I. Effects of simvastatin and ezetimibe on interleukin-6 and high-sensitivity C-reactive protein. Scand Cardiovasc J Suppl. 2013;47(1):20\u20137.","journal-title":"Scand Cardiovasc J Suppl"},{"issue":"9","key":"8817_CR3","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.amjcard.2011.12.015","volume":"109","author":"B Pitt","year":"2012","unstructured":"Pitt B, Loscalzo J, Monyak J, Miller E, Raichlen J. Comparison of lipid-modifying efficacy of rosuvastatin versus atorvastatin in patients with acute coronary syndrome (from the LUNAR study). Am J Cardiol. 2012;109(9):1239\u201346.","journal-title":"Am J Cardiol"},{"issue":"15","key":"8817_CR4","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","volume":"350","author":"CP Cannon","year":"2004","unstructured":"Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350(15):1495\u2013504.","journal-title":"N Engl J Med"},{"issue":"23","key":"8817_CR5","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1001\/jama.287.23.3087","volume":"287","author":"LK Newby","year":"2002","unstructured":"Newby LK, Kristinsson A, Bhapkar MV, Aylward PE, Dimas AP, Klein WW, et al. Early statin initiation and outcomes in patients with acute coronary syndromes. JAMA. 2002;287(23):3087\u201395.","journal-title":"JAMA"},{"issue":"11","key":"8817_CR6","volume":"10","author":"C Tie","year":"2015","unstructured":"Tie C, Gao K, Zhang N, Zhang S, Shen J, Xie X, Wang JA. Ezetimibe attenuates atherosclerosis associated with lipid reduction and inflammation inhibition. PLoS ONE. 2015;10(11): e0142430.","journal-title":"PLoS ONE"},{"issue":"5","key":"8817_CR7","doi-asserted-by":"crossref","first-page":"243","DOI":"10.12968\/bjcn.2015.20.5.243","volume":"20","author":"J Signy","year":"2015","unstructured":"Signy J, Signy M. The IMPROVE-IT study and ezetimibe. Br J Community Nurs. 2015;20(5):243\u20134.","journal-title":"Br J Community Nurs"},{"issue":"2","key":"8817_CR8","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.atherosclerosis.2004.10.021","volume":"179","author":"PT Sager","year":"2005","unstructured":"Sager PT, Capece R, Lipka L, Strony J, Yang B, Suresh R, et al. Effects of ezetimibe coadministered with simvastatin on C-reactive protein in a large cohort of hypercholesterolemic patients. Atherosclerosis. 2005;179(2):361\u20137.","journal-title":"Atherosclerosis"},{"issue":"12","key":"8817_CR9","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/j.amjcard.2003.08.048","volume":"92","author":"PT Sager","year":"2003","unstructured":"Sager PT, Melani L, Lipka L, Strony J, Yang B, Suresh R, et al. Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein. Am J Cardiol. 2003;92(12):1414\u20138.","journal-title":"Am J Cardiol"},{"issue":"2","key":"8817_CR10","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jacc.2015.09.105","volume":"67","author":"P Giral","year":"2016","unstructured":"Giral P, Hansel B, Chapman J. Dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression after PCI: PRECISE-IVUS. J Am Coll Cardiol. 2016;67(2):234.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"8817_CR11","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1185\/030079904125004213","volume":"20","author":"T Kosoglou","year":"2004","unstructured":"Kosoglou T, Statkevich P, Yang B, Suresh R, Zhu Y, Boutros T, et al. Pharmacodynamic interaction between ezetimibe and rosuvastatin. Curr Med Res Opin. 2004;20(8):1185\u201395.","journal-title":"Curr Med Res Opin"},{"issue":"7","key":"8817_CR12","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1185\/030079905X50642","volume":"21","author":"A Catapano","year":"2005","unstructured":"Catapano A, Brady WE, King TR, Palmisano J. Lipid altering-efficacy of ezetimibe co-administered with simvastatin compared with rosuvastatin: a meta-analysis of pooled data from 14 clinical trials. Curr Med Res Opin. 2005;21(7):1123\u201330.","journal-title":"Curr Med Res Opin"},{"issue":"10","key":"8817_CR13","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1185\/030079906X148364","volume":"22","author":"SS Daskalopoulou","year":"2006","unstructured":"Daskalopoulou SS, Mikhailidis DP. Ezetimibe\/simvastatin single tablet versus rosuvastatin in patients with hypercholesterolemia. Curr Med Res Opin. 2006;22(10):2037\u20139.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"8817_CR14","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2174\/157016111793744788","volume":"9","author":"T Ishibashi","year":"2011","unstructured":"Ishibashi T, Takeishi Y. Ezetimibe and vascular inflammation. Curr Vasc Pharmacol. 2011;9(1):99\u2013108.","journal-title":"Curr Vasc Pharmacol"},{"key":"8817_CR15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12944-017-0646-8","volume":"17","author":"C Ai","year":"2018","unstructured":"Ai C, Zhang S, He Q, Shi J. Comparing the combination therapy of ezetimibe and atorvastatin with atorvastatin monotherapy for regulating blood lipids: a systematic review and meta-analyse. Lipids Health Dis. 2018;17:1\u20139.","journal-title":"Lipids Health Dis"},{"issue":"5","key":"8817_CR16","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.jacc.2015.05.065","volume":"66","author":"K Tsujita","year":"2015","unstructured":"Tsujita K, Sugiyama S, Sumida H, Shimomura H, Yamashita T, Yamanaga K, et al. Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE-IVUS trial. J Am Coll Cardiol. 2015;66(5):495\u2013507.","journal-title":"J Am Coll Cardiol"},{"key":"8817_CR17","doi-asserted-by":"crossref","first-page":"7","DOI":"10.7573\/dic.212534","volume":"7","author":"M Vavlukis","year":"2018","unstructured":"Vavlukis M, Vavlukis A. Adding ezetimibe to statin therapy: latest evidence and clinical implications. Drugs in context. 2018;7:7.","journal-title":"Drugs in context."},{"key":"8817_CR18","unstructured":"Adams SP, Tsang M, Wright JM. Lipid-lowering efficacy of atorvastatin. Cochrane Database Syst Rev. 2015;2015(3)."},{"key":"8817_CR19","first-page":"415","volume":"8","author":"BAP Phan","year":"2012","unstructured":"Phan BAP, Dayspring TD, Toth PP. Ezetimibe therapy: mechanism of action and clinical update. Vasc Health Risk Manag. 2012;8:415\u201327.","journal-title":"Vasc Health Risk Manag"},{"issue":"9841","key":"8817_CR20","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","volume":"380","author":"B Mihaylova","year":"2012","unstructured":"Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes E, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet (London, England). 2012;380(9841):581\u201390.","journal-title":"Lancet (London, England)"},{"issue":"11","key":"8817_CR21","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.jacc.2021.07.016","volume":"78","author":"W Zhang","year":"2021","unstructured":"Zhang W, Speiser JL, Ye F, Tsai MY, Cainzos-Achirica M, Nasir K, et al. High-sensitivity C-reactive protein modifies the cardiovascular risk of lipoprotein (a) multi-ethnic study of atherosclerosis. J Am Coll Cardiol. 2021;78(11):1083\u201394.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"8817_CR22","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1161\/CIRCRESAHA.115.306656","volume":"118","author":"PM Ridker","year":"2016","unstructured":"Ridker PM. From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection. Circ Res. 2016;118(1):145\u201356.","journal-title":"Circ Res"},{"issue":"9S","key":"8817_CR23","doi-asserted-by":"crossref","first-page":"A33","DOI":"10.1016\/j.jacc.2006.08.011","volume":"48","author":"P Libby","year":"2006","unstructured":"Libby P, Ridker PM. Inflammation and atherothrombosis: from population biology and bench research to clinical practice. J Am Coll Cardiol. 2006;48(9S):A33\u201346.","journal-title":"J Am Coll Cardiol"},{"issue":"10384","key":"8817_CR24","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0140-6736(23)00215-5","volume":"401","author":"PM Ridker","year":"2023","unstructured":"Ridker PM, Bhatt DL, Pradhan AD, Glynn RJ, MacFadyen JG, Nissen SE. Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials. The Lancet. 2023;401(10384):1293\u2013301.","journal-title":"The Lancet"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-08817-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-025-08817-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-08817-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T14:44:45Z","timestamp":1743173085000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-025-08817-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,28]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["8817"],"URL":"https:\/\/doi.org\/10.1186\/s13063-025-08817-7","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,28]]},"assertion":[{"value":"6 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study received ethics approval from the Ethics Committee of Hormozgan University of Medical Sciences (IR.HUMS.REC.1396.133). Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"108"}}